Institutional Abilify settlement forecasting. Solve for compulsive behavior liability, financial loss recovery, and FDA warning relevance.
FDA DATA
2026 Statutory Sync
| Metric | Verification |
|---|---|
| FDA Warning | 2016 Active |
| Manufacturer | Bristol-Myers Squibb |
| Claim Status | Ongoing Settlements |
| Injury Class | Avg Settlement |
|---|---|
| Compulsive Gambling | $200,000 |
| Compulsive Shopping | $150,000 |
| Hypersexual Behavior | $175,000 |
| Factor | Multiplier |
|---|---|
| Gambling Severity | 2.5x |
| Documentation Proved | 1.25x Bonus |
| Audit Version | S-Class v2.6 |
Abilify settlements are governed by **Compulsive Propensity Loops**. Our engine audits recovery potentials based on documented financial destruction, behavior cessation timelines, and current FDA-backed legal protocols.
Audit of pathological financial loss
Post-drug recovery duration audit
FDA warning relevance calibration
"Calibrated against 2026 FDA Safety Communications, multi-district litigation (MDL) settlement trends, and Section 12 liability protocols."
A: Abilify lawsuits allege that manufacturers Bristol-Myers Squibb and Otsuka knew the drug caused compulsive behaviors like gambling and shopping but failed to warn patients until required by the FDA in 2016.
A: Eligible compulsive behaviors include pathological gambling, compulsive shopping/spending, binge eating, and hypersexual behavior that developed after starting Abilify.
A: Settlement values for 2026 depend on documented financial losses. Cases with severe losses ($100k+) can receive projected recovery ranges of $200,000 to $300,000+.
Don't let compulsive medical negligence go uncompensated. Initiate your official S-Class forensic Abilify audit.
INITIATE AUDIT NOW